MBX Biosciences announces positive Phase 1 topline results for MBX 1416 for PBH; cash $262.1M

MBX Biosciences, Inc.

MBX 1416 generally well-tolerated; no dose-related serious adverse events; mild/moderate ISRs in 88% resolved ~7 days.
Median half-life ~90 hours supports once-weekly dosing; Tmax 36-48h at steady state; dose-proportional PK.
GLP-1 increase within 60 mins of mixed meal test; slight acceleration of gastric emptying observed.
No meaningful effect on rosuvastatin exposure in drug-drug interaction portion.
Phase 2 in PBH patients expected to start 2H 2025; cash $262.1M as of Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.